Skip to content
Helix Biomedix logo with three teal DNA helix shapes on the right
  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Disease Focus
    • DNA Damage Response (DDR)
    • Xeroderma Pigmentosum
  • Programs
    • Pharma
    • Personal Care
  • News
    • Press Releases
    • Presentations
    • Scientific Publications
  • Investors
    • Stock Information
    • IR Updates
    • Proxy
    • Corporate Governance
  • Contact Page

Investor Relations Updates

Access the latest stockholder reports, press releases and company communications.

NEW REPORTS

Stockholder Update May 2026 [PDF]
Stockholder Update December 2025 [PDF]
Stockholder Update September 2025 [PDF]
Stockholder Update July 2025 [PDF]
Stockholder Update May 2025 [PDF]
Stockholder Update December 2024 [PDF]
Stockholder Update September 2024 [PDF]
Stockholder Update July 2024 [PDF]
Stockholder Update May 2024 [PDF]
Stockholder Update February 2024 [PDF]
Stockholder Update November 2023 [PDF]
Stockholder Update September 2023 [PDF]
Stockholder Update July 2023 [PDF]
Stockholder Update May 2023 [PDF]
Stockholder Update February 2023 [PDF]
Stockholder Update November 2022 [PDF]
Stockholder Update July 2022 [PDF]
Stockholder Update May 2022 [PDF]
Stockholder Update February 2022 [PDF]

Press Release on Shareholder Communications  [PDF]

COMPANY PROFILE

Helix BioMedix is a biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum.  Our legacy R&D established a proprietary library of patented bioactive peptides based on the body’s innate immunity.

  • Terms of Service and Privacy Policy
  • Accessibility Statement
  • Site Map

SEARCH

© 2025 HELIX BIOMEDIX, INC.
ALL RIGHTS RESERVED

Helix BioMedix Inc uses Accessibility Checker to monitor our website's accessibility. Read our Accessibility Policy.